Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Peritoneal Neoplasms 2Mesothelioma 1Malignant Solid Tumour 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 3Pemetrexed 2Paclitaxel 2Gemcitabine 2rucaparib 1relacorilant 1niraparib 1nintedanib 1liposomal doxorubicin 1atezolizumab 1Watchful Waiting 1Transurethral Resection of Prostate 1Pregnancy Tests 1Ocoxin 1Nivolumab 1Human Papillomavirus DNA Tests 1Fulvestrant 1E-3810 1Drug Therapy 1Darbepoetin alfa 1Colposcopy 1Cell Count 1Biopsy 1Bevacizumab 1Acetic Acid 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Genital Neoplasms, Female × nintedanib × Clear all
NCT02182245 2025-01-23

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Boehringer Ingelheim

Phase 1 Completed
22 enrolled

Genital Neoplasms, Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡